Unknown

Dataset Information

0

Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.


ABSTRACT: Recurrent malignant glioma carries a dismal prognosis, and novel therapies are needed. We examined the feasibility and safety of vaccination with irradiated autologous glioma cells mixed with irradiated GM-K562 cells in patients undergoing craniotomy for recurrent malignant glioma.We initiated a phase I study examining the safety of 2 doses of GM-K562 cells mixed with autologous cells. Primary endpoints were feasibility and safety. Feasibility was defined as the ability for 60% of enrolled subjects to initiate vaccination. Dose-limiting toxicity was assessed via a 3+3 dose-escalation format, examining irradiated tumor cells mixed with 5 × 10(6) GM-K562 cells or 1 × 10(7) GM-K562 cells. Eligibility required a priori indication for resection of a recurrent high-grade glioma. We measured biological activity by measuring delayed type hypersensitivity (DTH) responses, humoral immunity against tumor-associated antigens, and T-lymphocyte activation.Eleven patients were enrolled. Sufficient numbers of autologous tumor cells were harvested in 10 patients, all of whom went on to receive vaccine. There were no dose-limiting toxicities. Vaccination strengthened DTH responses to irradiated autologous tumor cells in most patients, and vigorous humoral responses to tumor-associated angiogenic cytokines were seen as well. T-lymphocyte activation was seen with significantly increased expression of CTLA-4, PD-1, 4-1BB, and OX40 by CD4(+) cells and PD-1 and 4-1BB by CD8(+) cells. Activation was coupled with vaccine-associated increase in the frequency of regulatory CD4(+) T lymphocytes.Vaccination with irradiated autologous tumor cells mixed with GM-K562 cells is feasible, well tolerated, and active in patients with recurrent malignant glioma. Clin Cancer Res; 22(12); 2885-96. ©2016 AACR.

SUBMITTER: Curry WT 

PROVIDER: S-EPMC4911283 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.

Curry William T WT   Gorrepati Ramana R   Piesche Matthias M   Sasada Tetsuro T   Agarwalla Pankaj P   Jones Pamela S PS   Gerstner Elizabeth R ER   Golby Alexandra J AJ   Batchelor Tracy T TT   Wen Patrick Y PY   Mihm Martin C MC   Dranoff Glenn G  

Clinical cancer research : an official journal of the American Association for Cancer Research 20160212 12


<h4>Purpose</h4>Recurrent malignant glioma carries a dismal prognosis, and novel therapies are needed. We examined the feasibility and safety of vaccination with irradiated autologous glioma cells mixed with irradiated GM-K562 cells in patients undergoing craniotomy for recurrent malignant glioma.<h4>Experimental design</h4>We initiated a phase I study examining the safety of 2 doses of GM-K562 cells mixed with autologous cells. Primary endpoints were feasibility and safety. Feasibility was defi  ...[more]

Similar Datasets

| S-EPMC5737123 | biostudies-literature
| S-EPMC7477145 | biostudies-literature
| S-EPMC6676100 | biostudies-literature
| S-EPMC9719861 | biostudies-literature
| S-EPMC2747203 | biostudies-other
| S-EPMC5761505 | biostudies-literature
| S-EPMC3951081 | biostudies-other
| S-EPMC4743035 | biostudies-literature
| S-EPMC4317836 | biostudies-other
| S-EPMC3922726 | biostudies-literature